Akari Therapeutics, Plc
- AKTX
- NASDAQ
- Biotechnology
- Antibody-Drug Conjugates
- Spliceosome-Targeted Cancer Therapy
$8.18
Today −5.60%Quote Oct 16, 2026, 08:00 PM UTC
−17.21%over the last month
Max drawdown −27.6%From 1-month high −18.7%3 months −23.3%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$749.02B
Quote Oct 16
Next earnings
Dec 4
Expected, not confirmed
Analyst target
$24.75
+202.6% from here
Floor
$8.09
1.1% below price
Where the price sits
8 analysts
Analyst range, low to high
$19.50$30.00
- Price $8.18
- Resistance $8.74
- Consensus $24.75
The price is just above its floor. Analysts' average target sits about 203% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about AKTXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
6